Literature DB >> 990158

Treatment of phaeochromocytoma and of clonidine withdrawal hypertension with labetalol.

E A Rosei, J J Brown, A F Lever, A S Robertson, J I Robertson, P M Trust.   

Abstract

1 Labetalol has been used as medical treatment in five patients with phaeochromocytoma. 2 In four of the five patients, blood pressure was satisfactorily controlled, and symptoms and signs were relieved. 3 Labetalol also provided satisfactory cover across surgery for the removal of tumours in two cases. 4 In one instance, it was not possible to give sufficient labetalol orally to suppress the attacks of phaeochromocytoma. This patient was not effectively controlled at operation with a combination of propranolol and phenoxybenzamine. 5 Intravenous labetalol rapidly lowered blood pressure and relieved symptoms in a patient experienced hypertensive crisis after clonidine withdrawal. 6 Labetalol is a useful addition to the medical treatment of phaeochromocytoma.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 990158

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  19 in total

Review 1.  Antihypertensive drugs: clinical pharmacology and therapeutic use.

Authors:  G L Wollam; R W Gifford; R C Tarazi
Journal:  Drugs       Date:  1977-12       Impact factor: 9.546

Review 2.  Labetalol: a review of its pharmacology and therapeutic use in hypertension.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1978-04       Impact factor: 9.546

3.  Circulatory effects of noradrenaline and adrenaline before and after labetalol.

Authors:  D A Richards; B N Prichard; R Hernández
Journal:  Br J Clin Pharmacol       Date:  1979-04       Impact factor: 4.335

Review 4.  The management of hypertension.

Authors:  B N Prichard; C W Owens
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

Review 5.  Comparison of labetalol with other anti-hypertensive drugs.

Authors:  B N Prichard; D A Richards
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

6.  Labetalol in the treatment of a patient with phaechromocytoma: a case report.

Authors:  R R Bailey
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

7.  The use of labetalol in Japan: results of multicentre clinical trials.

Authors:  T Takeda; Y Kaneko; T Omae; K Yoshinaga; Y Masuyama; T Nukada; R Shigiya
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

8.  Failure of blood pressure control by a new combined alpha- and beta-blocking agent (amosulalol) in a patient with pheochromocytoma.

Authors:  T Yamaguchi; C Irisawa; H Watanabe; S Kawamura; T Nakada
Journal:  Int Urol Nephrol       Date:  1991       Impact factor: 2.370

9.  Intravenous labetalol in the treatment of severe hypertension.

Authors:  A M Cumming; J J Brown; A F Lever; J I Robertson
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

Review 10.  Adverse drug reactions in patients with phaeochromocytoma: incidence, prevention and management.

Authors:  Graeme Eisenhofer; Graham Rivers; Alejandro L Rosas; Zena Quezado; William M Manger; Karel Pacak
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.